BTTX Stock Price, Better Therapeutics, . Quote, Chart

Market Summary

USD0.010.00

Market Closed

0.00%

BTTX Stock Price

View Fullscreen

BTTX RSI Chart

BTTX Valuation

Market Cap

474.0K

Price/Earnings (Trailing)

-0.02

EV/EBITDA

-0.06

Price/Free Cashflow

-0.02

MarketCap/EBT

-0.02

BTTX Price/Earnings (Trailing)

BTTX Profitability

Return on Equity

-435.37%

Return on Assets

-294.47%

Free Cashflow Yield

-5.5K%

BTTX Fundamentals

BTTX Earnings

Earnings (TTM)

-31.6M

Earnings Growth (Yr)

48.6%

Earnings Growth (Qtr)

22.76%

Breaking Down BTTX Revenue

Last 30 days

-50%

Last 90 days

-94.7%

Trailing 12 Months

-99.2%

How does BTTX drawdown profile look like?

BTTX Financial Health

Current Ratio

0.57

Debt/Equity

1.06

Debt/Cashflow

-3.38

BTTX Investor Care

Shares Dilution (1Y)

99.64%

Diluted EPS (TTM)

-1.16

Tracking the Latest Insider Buys and Sells of Better Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	perry david p	acquired	160,000	0.1905	839,895	executive chairman
Jan 09, 2024	perry david p	acquired	250,000	0.1699	1,471,450	executive chairman
Dec 18, 2023	wynholds kristin	acquired	-	-	25,362	chief product officer
Dec 18, 2023	miller leslie a.	acquired	-	-	3,587	principal accounting officer
Dec 18, 2023	berman mark a.	acquired	-	-	25,362	chief medical officer
Dec 18, 2023	armanino andrew j.	acquired	-	-	3,750	-
Dec 18, 2023	granger elder	acquired	-	-	3,750	-
Dec 18, 2023	perry david p	acquired	-	-	3,750	executive chairman
Dec 18, 2023	parker geoffrey m.	acquired	-	-	3,750	-
Dec 18, 2023	lavizzo-mourey risa j	acquired	-	-	3,750	-

Which funds bought or sold BTTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Aspire Private Capital, LLC	unchanged	-	-36.00	3.00	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-60.36	-144,322	38,640	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	2,015	2,015	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-11,181	11,427	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	reduced	-44.64	-5,196	2,018	-%
Feb 14, 2024	AMERIPRISE FINANCIAL INC	unchanged	-	-2,565	2,925	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	42.00	42.00	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	7,421	7,421	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	added	249	10,880	25,106	-%
Feb 14, 2024	Royal Bank of Canada	added	201	-	-	-%

Are Funds Buying or Selling BTTX?

Are funds buying BTTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BTTX

No. of Funds

Unveiling Better Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	mmcap international inc. spc	0.71%	356,270	SC 13G/A
Feb 12, 2024	david p. perry 2015 trust	28.4%	15,484,821	SC 13D/A
Jan 25, 2024	david p. perry 2015 trust	28.4%	14,644,140	SC 13D/A
Aug 14, 2023	david p. perry 2015 trust	32.5%	13,164,218	SC 13D/A
Jul 31, 2023	mmcap international inc. spc	9.53%	3,859,649	SC 13G
Apr 21, 2023	david p. perry 2015 trust	37.5%	11,913,813	SC 13D/A
Apr 13, 2023	mountain crest capital llc	4.4%	1,388,250	SC 13G/A
Feb 07, 2023	farallon capital partners, l.p.	0.3%	75,065	SC 13G/A

Recent SEC filings of Better Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	424B3	Prospectus Filed
Mar 15, 2024	8-K	Current Report
Mar 15, 2024	424B3	Prospectus Filed
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	424B3	Prospectus Filed
Mar 11, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	RW	RW
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Better Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Better Therapeutics, Inc. News

Latest updates

Better Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet													(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-7.6%	10,722	11,604	12,808	22,943	28,221	37,103	40,291	50,958	57,798	57,901	58,025	6,387	4,881
Current Assets	-1.0%	7,345	7,422	8,442	18,446	23,490	32,137	35,179	45,251	292	396	521	463	987
Cash Equivalents	6.4%	6,598	6,200	6,100	15,740	22,305	29,685	31,673	40,566	3,232	2,118	1,599	123	757
Net PPE	-11.3%	102	115	131	121	122	115	98.00	82.00	61.00	-	-	89.00	183
Liabilities	-7.7%	20,659	22,392	22,641	23,842	20,969	19,049	12,866	14,238	2,257	2,121	2,081	13,145	5,486
Current Liabilities	-6.7%	12,938	13,873	13,640	13,494	9,312	6,141	3,567	4,733	245	108	68.00	613	486
Long Term Debt	-9.4%	7,721	8,519	9,001	10,348	11,657	12,908	9,299	9,505	-	-	-	640	5,000
LT Debt, Current	15.7%	6,586	5,693	5,539	4,532	3,129	1,783	304	-	-	-	-	-	-
LT Debt, Non Current	-9.4%	7,721	8,519	9,001	10,348	11,657	12,908	9,299	9,505	-	-	-	640	5,000
Shareholder's Equity	-	-	-	-	-	7,252	18,054	27,425	36,720	-	5,000	5,000	23.00	-
Retained Earnings	-4.6%	-134,311	-128,400	-120,860	-111,503	-102,738	-91,333	-81,405	-71,743	-1,958	-313	-149	-31,408	-25,021
Additional Paid-In Capital	5.7%	124,370	117,658	111,025	110,602	109,988	109,385	108,828	108,461	-	5,313	5,149	24,649	-
Shares Outstanding	27.6%	40,578	31,797	23,852	23,851	23,693	23,499	23,413	23,603	10,753	10,708	10,685	11,147	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-198000.0%	-5,943	-3.00	-13,800	-6,337	-7,012	-6,726	-8,855	-15,851	-6,868	-5,482	-2,617	764*	-1.00	-
Share Based Compensation	-10.7%	427	478	410	449	608	401	366	561	23.00	28.00	34.00	119	7.00	-
Cashflow From Investing	113.1%	66.00	-503	-521	-360	-374	-407	-39.00	-472	-18.00	1.00	-582	-	-	-
Cashflow From Financing	9.8%	6,279	5,718	-435	132	6.00	5,145	1.00	53,657	8,000	6,000	4,675	25.00	-	-

BTTX Income Statement

2023-09-30

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 1,833	$ 5,477	$ 7,462	$ 13,391
Sales and marketing	1,392	1,557	5,200	5,284
General and administrative	2,116	3,962	8,629	11,265
Total operating expenses	5,341	10,996	21,291	29,940
Loss from operations	(5,341)	(10,996)	(21,291)	(29,940)
Interest expense, net	(518)	(406)	(1,512)	(1,052)
Loss before provision for income taxes	(5,859)	(11,402)	(22,803)	(30,992)
Provision for income taxes	3	3	5	3
Net loss	$ (5,862)	$ (11,405)	$ (22,808)	$ (30,995)
Net loss per share, basic	$ (0.15)	$ (0.48)	$ (0.73)	$ (1.32)
Net loss per share, diluted	$ (0.15)	$ (0.48)	$ (0.73)	$ (1.32)
Weighted-average shares used in computing net loss per share, basic	38,495,150	23,693,154	31,214,093	23,533,290
Weighted-average shares used in computing net loss per share, diluted	38,495,150	23,693,154	31,214,093	23,533,290

BTTX Balance Sheet

2023-09-30

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,598	$ 15,740
Prepaid expenses	674	2,496
Other current assets	73	210
Total current assets	7,345	18,446
Capitalized software development costs, net	2,792	3,888
Property and equipment, net	102	121
Other long-term assets	483	488
Total Assets	10,722	22,943
Current liabilities:
Accounts payable	2,308	3,035
Accrued payroll	1,886	2,301
Other accrued expenses	2,158	3,626
Current portion of long-term debt	6,586	4,532
Total current liabilities	12,938	13,494
Long-term debt, net of current portion and debt issuance costs	7,721	10,348
Total liabilities	20,659	23,842
Commitments and contingencies (Note 8)
Stockholders' deficit:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized as of September 30, 2023 and December 31, 2022 and 40,577,987 and 23,851,022 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	4	2
Additional paid-in capital	124,370	110,602
Accumulated deficit	(134,311)	(111,503)
Total Stockholders' Deficit	(9,937)	(899)
Total Liabilities and Stockholders' Deficit	$ 10,722	$ 22,943

About Better Therapeutics, Inc.

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

CEO	Mr. Frank L. Karbe
WEBSITE	bettertx.com
INDUSTRY	Biotechnology
EMPLOYEES	54

Better Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Better Therapeutics, Inc.? What does BTTX stand for in stocks?

BTTX is the stock ticker symbol of Better Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Better Therapeutics, Inc. (BTTX)?

As of Tue Apr 23 2024, market cap of Better Therapeutics, Inc. is 474.03 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BTTX stock?

You can check BTTX's fair value in chart for subscribers.

What is the fair value of BTTX stock?

You can check BTTX's fair value in chart for subscribers. The fair value of Better Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Better Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BTTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Better Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BTTX is over valued or under valued. Whether Better Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Better Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTTX.